Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
about
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanomaTreatment of metastatic melanoma: an overviewImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyAnal melanomaBiochemotherapy in the treatment of metastatic melanoma in selected patients.Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Treatment of malignant melanoma.State of melanoma: an historic overview of a field in transition.Metastasectomy for recurrent stage IV melanoma.Strategies for combining chemotherapy and biotherapy in melanoma.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisMetastatic melanoma: chemotherapy to biochemotherapy.Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.Novel dendritic cell-based vaccination in late stage melanomaA randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.Chemotherapy in the management of advanced cutaneous malignant melanoma.Surgical and radiation therapy management of recurrent anal melanoma.Cytokine therapy in melanoma.No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.BRAF and MEK inhibition in melanoma.Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatmentRecent Advances in Hydrogel-Based Drug Delivery for Melanoma Cancer Therapy: A Mini Review.Systemic therapy of malignant melanoma.Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.Biochemotherapy in patients with metastatic anorectal mucosal melanoma.Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.Biochemotherapy in patients with advanced head and neck mucosal melanoma.Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma.Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy
P2860
Q24246409-F693ECDC-53DB-4FE7-A7E1-FE985ED34E56Q24642384-91D2419E-181A-45F8-99CD-8B1C7A92D949Q26796309-F3422F00-85AA-4C4D-A39C-F80B0DCD95B4Q30437650-9AC579B1-71F3-469E-8395-0C7EC1B3785FQ33385028-37B536AB-FD6E-447F-BC31-024E65B44E33Q33502404-A64538E0-AEFD-4344-8215-E82747C3384DQ33667485-E30804F6-3341-4FB6-A1DB-3FAABE2BFC6FQ33689227-2B7B4DC3-3A60-4DD1-8350-904390DB07ADQ33693906-71A36628-031B-47E8-B583-086FFC416F4BQ33707209-4AF5C4F0-C46E-4C71-8BB0-CCDF7C04C5C4Q33900416-CA7B7BD1-484C-40B6-9C8D-F017B6147856Q34170003-BA8DABFC-758B-4E05-A8A1-F87824429032Q34573040-9F169794-E37B-4174-A47E-AC70A719B13DQ35093647-AA9EE9EA-D503-4C75-A05D-F9F0306BE1F2Q35886439-5E6114ED-E599-493E-9BBC-7F590AA34780Q36621278-D1CB9468-9CC2-4E4E-8874-0D767F006A07Q36643649-608ACD66-4B15-42D4-8FFD-53EFA6B06C16Q36980823-074640B5-2D1B-4621-8733-F8C64B017A4FQ37007984-E3F919FC-CB41-4A7E-BCD0-1A86F5F62148Q37522240-B3BCEE7B-8973-4E23-9E9C-7C88C7338EBEQ37756227-03265999-5523-4F31-907F-5B3FA5D2C20BQ38245356-C822DC21-3907-45C3-93A9-CBE32A2A0AC2Q38342905-6C8246FD-6CF0-4DC8-A72C-E83CAE6C924AQ39244850-84ACFB0C-40A0-471C-8EFF-FCD80CE5E151Q39661214-9F6250E0-5A76-4C5E-8E18-B9E585D94599Q41491310-F4635E4A-13A3-4316-BA7F-330454E5FEF0Q41611822-63D90512-8790-4E53-A914-D282141CEB5AQ43635735-28DFF846-D7B9-4E77-A477-F4D08A61F24EQ43707361-479AA167-9FEA-43B4-ABCE-C9A98AE9863BQ44813450-FF584EAA-BC51-4F6A-BB3C-F6EF1201C0F5Q46252210-37A08786-EACE-4045-A7CF-D9B1BC3F8C69Q46362485-CFB62883-FADD-4EEB-B485-71C4F229A274Q46515640-E5FC1087-C825-4CCE-9CD8-915374D747C7Q46527499-DAACE517-A83E-4D3A-B001-9FE7563492B8Q46705851-0A746DB1-A2DC-4CA6-A3A0-68134EAE07C0Q46708586-82998A71-7C29-49D1-A8C3-A54532E96FE2Q48109035-8C9C8B87-470E-4078-B4E7-35AA6E9D0A51Q53557662-12D130AA-AC7A-41DF-9C6B-056EEDF3FF38Q54067379-359A1994-7100-45FD-AC4C-48DA7487B96DQ59296605-E2791FA3-7232-479F-9469-1D5E42791E19
P2860
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@ast
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@en
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@nl
type
label
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@ast
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@en
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@nl
prefLabel
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@ast
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@en
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@nl
P2093
P1433
P1476
Treatment of metastatic melano ...... leukin-2 and interferon-alpha.
@en
P2093
A Bedikian
A C Buzaid
N Papadopoulos
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A010762
P577
1996-10-01T00:00:00Z